Which has higher valuation and earnings, HIK or HCM?

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hikma Pharmaceuticals £3.42B 0.96 £353.21M £176.00 8.97 HUTCHMED £549.12M 3.45 -£52.98M £2.00 109.10

Does the media favor HIK or HCM?

In the previous week, Hikma Pharmaceuticals had 3 more articles in the media than HUTCHMED. MarketBeat recorded 4 mentions for Hikma Pharmaceuticals and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.95 beat Hikma Pharmaceuticals' score of 0.32 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hikma Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, HCM or INDV?

Indivior has higher revenue and earnings than HUTCHMED. Indivior is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED £549.12M 3.45 -£52.98M £2.00 109.10 Indivior £1.40B 1.38 -£2.36M -£1.21 N/A

Is HCM or INDV more profitable?

HUTCHMED has a net margin of 163.84% compared to Indivior's net margin of 11.44%. HUTCHMED's return on equity of 36.88% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED 163.84% 36.88% -5.90% Indivior 11.44% -23.90% 2.37%

Which has preferable valuation and earnings, HCM or ERGO?

Ergomed has lower revenue, but higher earnings than HUTCHMED. Ergomed is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED £549.12M 3.45 -£52.98M £2.00 109.10 Ergomed £152.09M 0.00 £15M £0.29 N/A

Is HCM or ERGO more profitable?

HUTCHMED has a net margin of 163.84% compared to Ergomed's net margin of 9.87%. HUTCHMED's return on equity of 36.88% beat Ergomed's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED 163.84% 36.88% -5.90% Ergomed 9.87% 18.08% 10.16%

HUTCHMED (HCM) Competitors

GBX 215 -9.00 (-4.02%)

As of 12:00 PM Eastern

Compare

HCM vs. DPH, HIK, INDV, VEC, and ERGO

Should you buy HUTCHMED stock or one of its competitors? HUTCHMED's main competitors and comparable companies include Dechra Pharmaceuticals (DPH), Hikma Pharmaceuticals (HIK), Indivior (INDV), Vectura Group (VEC), and Ergomed (ERGO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HUTCHMED compare to Dechra Pharmaceuticals?

HUTCHMED (LON:HCM) and Dechra Pharmaceuticals (LON:DPH) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

HUTCHMED has a net margin of 163.84% compared to Dechra Pharmaceuticals' net margin of -3.66%. HUTCHMED's return on equity of 36.88% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	163.84%	36.88%	-5.90%
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%

In the previous week, HUTCHMED had 1 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 1 mentions for HUTCHMED and 0 mentions for Dechra Pharmaceuticals. HUTCHMED's average media sentiment score of 0.95 beat Dechra Pharmaceuticals' score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Overall Sentiment
HUTCHMED	Positive
Dechra Pharmaceuticals	Neutral

20.7% of HUTCHMED shares are owned by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by company insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

HUTCHMED has a beta of 0.428, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Dechra Pharmaceuticals has higher revenue and earnings than HUTCHMED. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£549.12M	3.45	-£52.98M	£2.00	109.10
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A

Summary

HUTCHMED and Dechra Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does HUTCHMED compare to Hikma Pharmaceuticals?

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 20.7% of HUTCHMED shares are held by institutional investors. 22.3% of Hikma Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Hikma Pharmaceuticals currently has a consensus target price of GBX 2,085.83, indicating a potential upside of 32.10%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.42B	0.96	£353.21M	£176.00	8.97
HUTCHMED	£549.12M	3.45	-£52.98M	£2.00	109.10

HUTCHMED has a net margin of 163.84% compared to Hikma Pharmaceuticals' net margin of 11.31%. HUTCHMED's return on equity of 36.88% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	11.31%	15.05%	9.40%
HUTCHMED	163.84%	36.88%	-5.90%

Hikma Pharmaceuticals has a beta of 0.662, meaning that its share price is 34% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, meaning that its share price is 57% less volatile than the broader market.

In the previous week, Hikma Pharmaceuticals had 3 more articles in the media than HUTCHMED. MarketBeat recorded 4 mentions for Hikma Pharmaceuticals and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.95 beat Hikma Pharmaceuticals' score of 0.32 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hikma Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Hikma Pharmaceuticals beats HUTCHMED on 11 of the 16 factors compared between the two stocks.

How does HUTCHMED compare to Indivior?

HUTCHMED (LON:HCM) and Indivior (LON:INDV) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

20.7% of HUTCHMED shares are held by institutional investors. Comparatively, 86.0% of Indivior shares are held by institutional investors. 2.8% of HUTCHMED shares are held by company insiders. Comparatively, 3.4% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

HUTCHMED has a beta of 0.428, meaning that its share price is 57% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Indivior has higher revenue and earnings than HUTCHMED. Indivior is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£549.12M	3.45	-£52.98M	£2.00	109.10
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A

HUTCHMED has a net margin of 163.84% compared to Indivior's net margin of 11.44%. HUTCHMED's return on equity of 36.88% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	163.84%	36.88%	-5.90%
Indivior	11.44%	-23.90%	2.37%

In the previous week, HUTCHMED had 1 more articles in the media than Indivior. MarketBeat recorded 1 mentions for HUTCHMED and 0 mentions for Indivior. HUTCHMED's average media sentiment score of 0.95 beat Indivior's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Overall Sentiment
HUTCHMED	Positive
Indivior	Neutral

Summary

HUTCHMED beats Indivior on 8 of the 13 factors compared between the two stocks.

How does HUTCHMED compare to Vectura Group?

Vectura Group (LON:VEC) and HUTCHMED (LON:HCM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

20.7% of HUTCHMED shares are held by institutional investors. 2.8% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, HUTCHMED had 1 more articles in the media than Vectura Group. MarketBeat recorded 1 mentions for HUTCHMED and 0 mentions for Vectura Group. HUTCHMED's average media sentiment score of 0.95 beat Vectura Group's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Overall Sentiment
Vectura Group	Neutral
HUTCHMED	Positive

HUTCHMED has a net margin of 163.84% compared to Vectura Group's net margin of 0.00%. HUTCHMED's return on equity of 36.88% beat Vectura Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vectura Group	N/A	N/A	N/A
HUTCHMED	163.84%	36.88%	-5.90%

Vectura Group has higher earnings, but lower revenue than HUTCHMED. Vectura Group is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vectura Group	£190.60M	0.00	N/A	£20.10	N/A
HUTCHMED	£549.12M	3.45	-£52.98M	£2.00	109.10

Summary

HUTCHMED beats Vectura Group on 8 of the 10 factors compared between the two stocks.

How does HUTCHMED compare to Ergomed?

HUTCHMED (LON:HCM) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

In the previous week, HUTCHMED had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for HUTCHMED and 0 mentions for Ergomed. HUTCHMED's average media sentiment score of 0.95 beat Ergomed's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Overall Sentiment
HUTCHMED	Positive
Ergomed	Neutral

HUTCHMED has a beta of 0.428, meaning that its share price is 57% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

20.7% of HUTCHMED shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by company insiders. Comparatively, 18.2% of Ergomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

HUTCHMED has a net margin of 163.84% compared to Ergomed's net margin of 9.87%. HUTCHMED's return on equity of 36.88% beat Ergomed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	163.84%	36.88%	-5.90%
Ergomed	9.87%	18.08%	10.16%

Ergomed has lower revenue, but higher earnings than HUTCHMED. Ergomed is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£549.12M	3.45	-£52.98M	£2.00	109.10
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

Summary

HUTCHMED and Ergomed tied by winning 6 of the 12 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCM vs. The Competition

Export

Metric	HUTCHMED	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£1.87B	£12.21B	£7.10B	£2.80B
Dividend Yield	4.63%	2.63%	2.53%	6.18%
P/E Ratio	107.50	797.16	274.61	366.17
Price / Sales	3.40	751.67	601.02	89,425.29
Price / Cash	2.49	81.79	77.38	27.89
Price / Book	2.46	10.47	10.92	6.83
Net Income	-£52.98M	£2.83B	£3.50B	£5.89B
7 Day Performance	-0.46%	-1.64%	-2.11%	-0.75%
1 Month Performance	19.78%	-5.76%	-6.34%	16.84%
1 Year Performance	-8.90%	-3.79%	8.81%	16.40%

HUTCHMED Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCM HUTCHMED	N/A	GBX 215 -4.0%	N/A	-3.0%	£1.87B	£549.12M	107.50	1,760
DPH Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	£4.40B	£761.50M	N/A	2,457
HIK Hikma Pharmaceuticals	4.7176 of 5 stars	GBX 1,590 -2.2%	GBX 2,085.83 +31.2%	-12.4%	£3.29B	£3.42B	9.03	9,500
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	+0.0%	£1.93B	£1.40B	N/A	1,000	Gap Up High Trading Volume
VEC Vectura Group	N/A	N/A	N/A	N/A	£1.01B	£190.60M	8.20	9,200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HCM) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HUTCHMED (HCM) Competitors

HCM vs. DPH, HIK, INDV, VEC, and ERGO

How does HUTCHMED compare to Dechra Pharmaceuticals?

Summary

How does HUTCHMED compare to Hikma Pharmaceuticals?

Summary

How does HUTCHMED compare to Indivior?

Summary

How does HUTCHMED compare to Vectura Group?

Summary

How does HUTCHMED compare to Ergomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HUTCHMED (HCM) Competitors

HCM vs. DPH, HIK, INDV, VEC, and ERGO

How does HUTCHMED compare to Dechra Pharmaceuticals?

Is HCM or DPH more profitable?

Does the media prefer HCM or DPH?

Do institutionals & insiders have more ownership in HCM or DPH?

Which has more volatility & risk, HCM or DPH?

Which has preferable earnings & valuation, HCM or DPH?

Summary

How does HUTCHMED compare to Hikma Pharmaceuticals?

Do insiders and institutionals believe in HIK or HCM?

Do analysts rate HIK or HCM?

Which has higher valuation and earnings, HIK or HCM?

Is HIK or HCM more profitable?

Which has more volatility and risk, HIK or HCM?

Does the media favor HIK or HCM?

Summary

How does HUTCHMED compare to Indivior?

Do institutionals and insiders hold more shares of HCM or INDV?

Which has more volatility and risk, HCM or INDV?

Which has higher valuation and earnings, HCM or INDV?

Is HCM or INDV more profitable?

Does the media prefer HCM or INDV?

Summary

How does HUTCHMED compare to Vectura Group?

Do institutionals and insiders believe in VEC or HCM?

Does the media prefer VEC or HCM?

Is VEC or HCM more profitable?

Which has better earnings & valuation, VEC or HCM?

Summary

How does HUTCHMED compare to Ergomed?

Does the media refer more to HCM or ERGO?

Which has more risk and volatility, HCM or ERGO?

Do insiders and institutionals believe in HCM or ERGO?

Is HCM or ERGO more profitable?

Which has preferable valuation and earnings, HCM or ERGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools